Overview

Efficacy and Safety of T+A+RAD in HCC

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is An Open-label, Single-arm Exploratory Study to determine the efficacy and safety of Multifocal Stereotactic Radiotherapy Combined with Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Collaborator:

Roche Pharma AG

Treatments:

Atezolizumab
Bevacizumab